BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35000863)

  • 21. Outcome after resection for invasive intraductal papillary mucinous neoplasia is similar to conventional pancreatic ductal adenocarcinoma.
    Holmberg M; Ghorbani P; Gilg S; Del Chiaro M; Arnelo U; Löhr JM; Sparrelid E
    Pancreatology; 2021 Oct; 21(7):1371-1377. PubMed ID: 34426077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonoperative management of main pancreatic duct-involved intraductal papillary mucinous neoplasm might be indicated in select patients.
    Roch AM; DeWitt JM; Al-Haddad MA; Schmidt CM; Ceppa EP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    J Am Coll Surg; 2014 Jul; 219(1):122-9. PubMed ID: 24862887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting dysplasia and invasive carcinoma in intraductal papillary mucinous neoplasms of the pancreas: development of a preoperative nomogram.
    Correa-Gallego C; Do R; Lafemina J; Gonen M; D'Angelica MI; DeMatteo RP; Fong Y; Kingham TP; Brennan MF; Jarnagin WR; Allen PJ
    Ann Surg Oncol; 2013 Dec; 20(13):4348-55. PubMed ID: 24046103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas.
    Poultsides GA; Reddy S; Cameron JL; Hruban RH; Pawlik TM; Ahuja N; Jain A; Edil BH; Iacobuzio-Donahue CA; Schulick RD; Wolfgang CL
    Ann Surg; 2010 Mar; 251(3):470-6. PubMed ID: 20142731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pancreatic resection for intraductal papillary mucinous neoplasm- a thirteen-year single center experience.
    Marsoner K; Haybaeck J; Csengeri D; Waha JE; Schagerl J; Langeder R; Mischinger HJ; Kornprat P
    BMC Cancer; 2016 Nov; 16(1):844. PubMed ID: 27809876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of a Revised Management Strategy for Patients With Intraductal Papillary Mucinous Neoplasms Involving the Main Pancreatic Duct.
    Sugimoto M; Elliott IA; Nguyen AH; Kim S; Muthusamy VR; Watson R; Hines OJ; Dawson DW; Reber HA; Donahue TR
    JAMA Surg; 2017 Jan; 152(1):e163349. PubMed ID: 27829085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas.
    Pea A; Yu J; Rezaee N; Luchini C; He J; Dal Molin M; Griffin JF; Fedor H; Fesharakizadeh S; Salvia R; Weiss MJ; Bassi C; Cameron JL; Zheng L; Scarpa A; Hruban RH; Lennon AM; Goggins M; Wolfgang CL; Wood LD
    Ann Surg; 2017 Jul; 266(1):133-141. PubMed ID: 27433916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Malignant potential of intraductal papillary mucinous neoplasms of the pancreas.
    Nakajima Y; Yamada T; Sho M
    Surg Today; 2010 Sep; 40(9):816-24. PubMed ID: 20740343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology.
    Schmidt CM; White PB; Waters JA; Yiannoutsos CT; Cummings OW; Baker M; Howard TJ; Zyromski NJ; Nakeeb A; DeWitt JM; Akisik FM; Sherman S; Pitt HA; Lillemoe KD
    Ann Surg; 2007 Oct; 246(4):644-51; discussion 651-4. PubMed ID: 17893501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carbohydrate Antigen 19-9 Is an Invasive Malignancy Preoperative Prognostic Factor for Intraductal Papillary Mucinous Neoplasms.
    Suzuki S; Shimoda M; Shimazaki J; Oshiro Y; Nishda K; Orimoto N; Nagakawa Y; Tsuchida A
    Eur Surg Res; 2021; 62(4):262-270. PubMed ID: 34344012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validating a simple scoring system to predict malignancy and invasiveness of intraductal papillary mucinous neoplasms of the pancreas.
    Shin SH; Han DJ; Park KT; Kim YH; Park JB; Kim SC
    World J Surg; 2010 Apr; 34(4):776-83. PubMed ID: 20127242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-emptive resection for intraductal papillary mucinous neoplasia - Long-term outcome is similar between non-invasive and early invasive lesions in a tertiary single center.
    Djoumi Y; Sadr-Azodi O; Vujasinovic M; Del Chiaro M; Sparrelid E; Ghorbani P; Holmberg M
    Pancreatology; 2023 Jun; 23(4):389-395. PubMed ID: 37002181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival.
    Gavazzi F; Capretti G; Giordano L; Ridolfi C; Spaggiari P; Sollai M; Carrara S; Nappo G; Bozzarelli S; Zerbi A
    Dig Liver Dis; 2022 Jun; 54(6):826-833. PubMed ID: 34219044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathologic study of the MIB-1 labeling index (Ki67) and postoperative prognosis for intraductal papillary mucinous neoplasms and ordinary ductal adenocarcinoma.
    Takeshita A; Kimura W; Hirai I; Takasu N; Moriya T; Tezuka K; Watanabe T
    Pancreas; 2012 Jan; 41(1):114-20. PubMed ID: 22143341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Invasive carcinoma originating in an intraductal papillary mucinous neoplasm of the pancreas: a clinicopathologic comparison with a common type of invasive ductal carcinoma.
    Shimada K; Sakamoto Y; Sano T; Kosuge T; Hiraoka N
    Pancreas; 2006 Apr; 32(3):281-7. PubMed ID: 16628084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma.
    Rezaee N; Barbon C; Zaki A; He J; Salman B; Hruban RH; Cameron JL; Herman JM; Ahuja N; Lennon AM; Weiss MJ; Wood LD; Wolfgang CL
    HPB (Oxford); 2016 Mar; 18(3):236-46. PubMed ID: 27017163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas.
    Schnelldorfer T; Sarr MG; Nagorney DM; Zhang L; Smyrk TC; Qin R; Chari ST; Farnell MB
    Arch Surg; 2008 Jul; 143(7):639-46; discussion 646. PubMed ID: 18645105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of spatio-temporal recurrence pattern on overall survival for invasive intraductal papillary mucinous neoplasia - A comparison with pancreatic ductal adenocarcinoma.
    Holmberg M; Linder S; Kordes M; Liljefors M; Ghorbani P; Löhr JM; Sparrelid E
    Pancreatology; 2022 Jun; 22(5):598-607. PubMed ID: 35501218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New Model for Predicting Malignancy in Patients With Intraductal Papillary Mucinous Neoplasm.
    Shimizu Y; Hijioka S; Hirono S; Kin T; Ohtsuka T; Kanno A; Koshita S; Hanada K; Kitano M; Inoue H; Itoi T; Ueki T; Matsuo K; Yanagisawa A; Yamaue H; Sugiyama M; Okazaki K
    Ann Surg; 2020 Jul; 272(1):155-162. PubMed ID: 30499803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pancreatic main-duct involvement in branch-duct IPMNs: an underestimated risk.
    Fritz S; Klauss M; Bergmann F; Strobel O; Schneider L; Werner J; Hackert T; Büchler MW
    Ann Surg; 2014 Nov; 260(5):848-55; discussion 855-6. PubMed ID: 25379856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.